J&J's Ethicon to acquire sphincter specialist Torax Medical

In its acquisition of Torax, Johnson & Johnson would add a treatment for gastroesophageal reflux disease that does not alter a patient's anatomy.

Johnson & Johnson’s Ethicon unit has agreed to acquire Torax Medical, which markets devices for the treatment of gastrointestinal conditions stemming from sphincter issues. The transaction amount was not disclosed.

In the deal, J&J will pick up a minimally invasive treatment for gastroesophageal reflux disease, the Linx Reflux Management system. It is a small, flexible band of magnetic titanium beads that helps prevent reflux by stopping the lower esophageal sphincter from opening due to stomach pressure.

Acquiring the device will allow J&J to offer patients a minimally invasive alternative to laparoscopic Nissen fundoplication, which involves wrapping the upper part of the stomach around the esophagus and stitching it in place.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Privately held Torax raised $25 million in a Series E round last summer, which it pegged for the scaling of its products aimed at chronic conditions caused by weak sphincter muscles. These include the Linx system and the Fenix Continence Restoration System, for fecal incontinence.

The Fenix system works similarly to the Linx device: The band of magnetic beads minimizes involuntary opening of the anal canal, decreasing the chance of severe incontinence.

The deal comes nearly a month after the conglomerate announced it was considering selling off its diabetes device businesses, whole or in parts, and just weeks after it said its medical device chairman, Gary Pruden, would step down.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.